STOCK TITAN

Nutriband Warrant (NTRBW) Financials

NTRBW NASDAQ
FY2026 annual
Revenue $2.0M -4.8% YoY
Net Income -$8.2M n/m YoY
EPS (Diluted) -$2.58 YoY not available
Free Cash Flow -$5.1M n/m YoY
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2027, ended Jul 31, 2026 Reported Currency USD FYE January

Newest figures come from the 10-Q for Q2 FY2027, filed Sep 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NTRBW SEC filings page.

Nutriband Inc. Warrant (NTRBW) reported $2.0M in revenue for fiscal year 2026, down 4.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NTRBW FY2026

Nutriband remains a development-stage business: modest sales fund neither escalating overhead nor product investment without outside financing.

In FY2026, revenue fell 4.8% while SG&A rose 62.1%. Gross margin then fell 6.9 percentage points, showing cost growth and weaker unit economics arriving together rather than scale absorbing overhead.

R&D consumed 92.9% of revenue, while operating cash flow was -$5.1M; that pairing describes a company still funding development before reaching commercial scale. Free cash flow was also -$5.1M because capital expenditures were just $5K, so the cash requirement is operational rather than an equipment buildout.

Financing cash flow supplied $5.4M against operating cash flow of -$5.1M; the business therefore funded its cash needs externally rather than through operations. The current ratio recovered to 6.4x as current liabilities fell 20.2%, but that short-term cushion does not change the underlying reliance on financing.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 50 / 100
Financial Health Score 50/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Nutriband Inc. Warrant's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
33

Nutriband Inc. Warrant held $4.6M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $5.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Nutriband Inc. Warrant scores 33/100 among other emerging companies.

Dilution
57

Nutriband Inc. Warrant had 12M shares outstanding at the end of fiscal year 2026. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Nutriband Inc. Warrant scores 57/100 among other emerging companies.

R&D Intensity
49

Nutriband Inc. Warrant spent $1.9M on research and development in fiscal year 2026, which was 18.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Nutriband Inc. Warrant scores 49/100 among other emerging companies.

Revenue Progress
43

Nutriband Inc. Warrant reported revenue of $2.0M in fiscal year 2026, against $2.1M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and Nutriband Inc. Warrant scores 43/100 among other emerging companies.

Burn Trend
31

Nutriband Inc. Warrant's operations used $5.1M of cash in fiscal year 2026, against $4.6M used in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Nutriband Inc. Warrant scores 31/100 among other emerging companies.

Balance Sheet
89

Nutriband Inc. Warrant's cash, cash equivalents and investments came to $4.6M at the end of fiscal year 2026, against $868K of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Nutriband Inc. Warrant scores 89/100 among other emerging companies.

Piotroski F-Score Partial
3/8

Nutriband Inc. Warrant passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing
N/A

Nutriband Inc. Warrant reported a net loss of $8.2M while operations used $5.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Nutriband Inc. Warrant reported an operating loss of $8.3M against $23K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$438K
YoY-29.7%
QoQ+0.9%
5Y CAGR+15.4%

Nutriband Inc. Warrant generated $438K in revenue in Q2 2027. This represents a decrease of 29.7% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

EBITDA
-$857K
YoYn/m
QoQn/m
5Y CAGRn/m

Nutriband Inc. Warrant's EBITDA was -$857K in Q2 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$881K
YoYn/m
QoQn/m
5Y CAGRn/m

Nutriband Inc. Warrant reported a net loss of $881K in Q2 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.07
QoQn/m

Nutriband Inc. Warrant earned -$0.07 per diluted share (EPS) in Q2 2027. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$3.4M
YoY-51.1%
QoQ-14.6%
5Y CAGR+62.3%

Nutriband Inc. Warrant held $3.4M in cash as of Q2 2027; no long-term debt figure is on record for that period.

Shares Outstanding
12M
QoQn/m

Nutriband Inc. Warrant had 12M shares outstanding in Q2 2027. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Free Cash Flow

Not reported for Q2 2027.

Dividends Per Share

Not reported for Q2 2027.

Margins & Returns

Gross Margin
41.6%
YoY+16.4pp
QoQ-3.8pp
5Y change+41.6pp

Nutriband Inc. Warrant's gross margin was 41.6% in Q2 2027, indicating the percentage of revenue retained after direct costs. This is up 16.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.8 percentage points.

Return on Equity
-16.5%
YoY+7.0pp
QoQ+4.2pp
5Y change-9.4pp

Nutriband Inc. Warrant's quarterly ROE was -16.5% in Q2 2027: one quarter's net income over shareholder equity, not annualized. This is up 7.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.2 percentage points.

Operating Margin

Not shown for Q2 2027: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2027: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$322K
YoY-42.7%
QoQ+30.3%

Nutriband Inc. Warrant invested $322K in research and development in Q2 2027. This represents a decrease of 42.7% from the same quarter a year earlier. Against the prior quarter it is up 30.3%.

Share Buybacks

Not reported for Q2 2027.

Capital Expenditures

Not reported for Q2 2027.

NTRBW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NTRBW quarterly income statement
MetricQ2'2710-QQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-Q
Revenue$438K-29.7%$433K-35.1%$401K-37.6%$346K-46.4%$622K+40.6%$667K+63.4%$642K+22.4%$646K+50.9%
Cost of Revenue$256K-45.1%$237K-43.1%$312K-12.5%$278K-39.0%$466K+36.4%$415K+70.4%$356K-32.1%$455K+6.3%
Gross Profit$182K+15.9%$197K-21.9%$89K-68.9%$69K-64.1%$157K+54.5%$252K+52.9%$286K-12.5%$191K+19.6%
R&D Expenses$322K-42.7%$247K-63.8%$188K-61.6%$457K-48.1%$563K-27.3%$683K-29.9%$490K-13.0%$881K+59.7%
SG&A Expenses$750K-53.0%$1.2M+22.6%$922K-47.6%$3.5M+373.7%$1.6M+116.7%$982K-9.0%$1.8M+90.4%$737K-44.6%
Operating Income-$891Kn/m-$1.3Mn/m-$1.0Mn/m-$3.9Mn/m-$2.0Mn/m-$1.4Mn/m-$5.6Mn/m-$1.4Mn/m
EBITDA-$857Kn/m-$1.2Mn/m-$985Kn/m-$3.8Mn/m-$1.9Mn/m-$1.4Mn/m-$5.5Mn/m-$1.4Mn/m
Interest Expense$5K-15.6%$5K+96.5%$9K-11.4%$6K+37.6%$6K+15.0%$3K-1.1%$10K-57.9%$4K-90.0%
Net Income-$881Kn/m-$1.2Mn/m-$968Kn/m-$3.9Mn/m-$2.0Mn/m-$1.4Mn/m-$5.5Mn/m-$1.4Mn/m
EPS (Basic)-$0.07-$0.10n/m-$0.04-$0.32n/m-$2.12-$0.12n/m-$0.51n/m-$0.12n/m
EPS (Diluted)-$0.07-$0.10n/m-$0.04-$0.32n/m-$2.12-$0.12n/m-$0.51n/m-$0.12n/m
Diluted Shares (Avg)12M12M+9.3%N/A12M+8.6%11M11M+21.5%N/A11M+41.7%

Not reported in any period shown, so not listed: Income Tax.

NTRBW Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NTRBW quarterly balance sheet
MetricQ2'2710-QQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-Q
Total Assets$6.3M-38.2%$6.9M+12.0%$7.5M+1.0%$8.4M-32.9%$10.2M-25.4%$6.2M-59.4%$7.5M-0.6%$12.5M+47.2%
Current Assets$3.8M-49.2%$4.4M+27.6%$5.0M+4.1%$5.8M-6.1%$7.5M+3.8%$3.4M-60.7%$4.8M+369.2%$6.2M+209.6%
Cash & Equivalents$3.4M-51.1%$4.0M+35.2%$4.6M+6.1%$5.3M-6.8%$7.0M+3.5%$3.0M-64.5%$4.3M+774.7%$5.7M+350.3%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$171K+23.7%$121K-43.6%$118K-44.4%$136K-19.2%$138K-38.3%$215K+27.8%$212K+25.8%$168K-3.6%
Accounts Receivable$24K-85.3%$3K-97.2%$118K+60.3%$148K+34.6%$161K+136.4%$94K+10.6%$74K-50.3%$110K-35.4%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$1.7M0.0%$1.7M0.0%$1.7M0.0%$1.7M-65.8%$1.7M-65.8%$1.7M-65.8%$1.7M-65.8%$5.0M0.0%
Total Liabilities$964K-42.7%$902K-14.0%$868K-16.6%$870K-33.6%$1.7M+43.5%$1.0M-41.5%$1.0M-3.5%$1.3M-53.4%
Current Liabilities$907K-42.3%$832K-10.0%$784K-20.2%$773K-38.1%$1.6M+42.4%$925K-34.7%$983K-1.6%$1.2M+73.8%
Non-Current Liabilities$57K-48.4%$70K-43.3%$84K+44.6%$98K+53.3%$111K+60.5%$124K-67.0%$58K-27.1%$64K-97.0%
Total Equity$5.3M-37.3%$6.0M+17.4%$6.7M+3.9%$7.5M-32.8%$8.5M-31.8%$5.1M-61.8%$6.4M-0.1%$11.2M+96.7%
Retained Earnings-$48.8Mn/m-$47.9Mn/m-$46.7Mn/m-$45.7Mn/m-$41.9Mn/m-$39.9Mn/m-$38.5Mn/m-$32.9Mn/m

Not reported in any period shown, so not listed: Long-Term Debt.

NTRBW Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NTRBW quarterly cash flow statement
MetricQ2'2710-QQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-Q
Operating Cash Flow-$585Kn/m-$563Kn/m-$732Kn/m-$1.8Mn/m-$1.3Mn/m-$1.3Mn/m-$1.2Mn/m-$1.0Mn/m
Depreciation & Amortization$33K-41.9%$34K-40.5%$36K-50.8%$43K-41.3%$57K-18.0%$57K-16.8%$73K+5.1%$73K+8.7%
Stock-Based CompensationN/A$552KN/AN/AN/AN/AN/AN/A
Capital ExpendituresN/AN/A$0n/m$0-100.0%$0-100.0%$5K-14.1%$0-100.0%$47Kn/m
Free Cash FlowN/AN/A-$732Kn/m-$1.8Mn/m-$1.3Mn/m-$1.3Mn/m-$1.2Mn/m-$1.1Mn/m
Investing Cash FlowN/AN/A$0n/m$0n/m$0n/m-$5Kn/m$0n/m-$47Kn/m
Financing Cash Flow$430-100.0%-$6Kn/m-$5Kn/m$70Kn/m$5.3Mn/m-$5K-100.1%-$147Kn/m-$5Kn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NTRBW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NTRBW quarterly financial ratios
MetricQ2'2710-QQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-Q
Gross Margin41.6%+16.4pp45.4%+7.7pp22.2%-22.3pp19.8%-9.8pp25.2%+2.3pp37.8%-2.6pp44.5%-17.8pp29.6%-7.8pp
Operating Margin-203.6%-289.4%-254.8%-1121.3%-321.8%-211.8%-865.3%-220.9%
Net Margin-201.3%-286.6%-241.6%-1119.0%-321.4%-208.1%-858.8%-211.0%
Return on Equity-16.5%+7.0pp-20.7%+6.5pp-14.5%+71.3pp-51.3%-39.2pp-23.5%-9.9pp-27.2%-13.0pp-85.8%-56.6pp-12.1%+18.7pp
Return on Assets-14.0%+5.7pp-18.0%+4.6pp-12.8%+61.0pp-46.0%-35.1pp-19.7%-7.2pp-22.6%-10.1pp-73.9%-48.8pp-10.9%+9.8pp
Current Ratio4.21-0.6x5.26+1.6x6.36+1.5x7.53+2.6x4.78-1.8x3.71-2.5x4.88+3.9x4.96+2.2x
Liabilities-to-Equity0.180.0x0.15-0.1x0.130.0x0.120.0x0.20+0.1x0.21+0.1x0.160.0x0.12-0.4x
Asset Turnover0.070.0x0.060.0x0.050.0x0.040.0x0.060.0x0.11+0.1x0.090.0x0.050.0x
FCF MarginN/AN/A-182.6%-506.4%-211.0%-201.1%-192.9%-163.6%

Not reported in any period shown, so not listed: Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Nutriband Inc. Warrant NTRBW FY2026 $2.0M -$8.2M N/A N/A 50/100
Aspire-Lakewood Holdings, Inc. Warrant ASBPW FY2025 $6K N/A N/A N/A —
SAB Biotherapeutics, Inc. Warrant SABSW FY2025 $0 $13.3M N/A N/A —
Tevogen Inc. Warrant TVGNW FY2025 N/A N/A N/A N/A —

Frequently Asked Questions

What is Nutriband Inc. Warrant's annual revenue?

Nutriband Inc. Warrant (NTRBW) reported $2.0M in total revenue for fiscal year 2026. This represents a -4.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Nutriband Inc. Warrant's revenue growing?

Nutriband Inc. Warrant (NTRBW) revenue declined by 4.8% year-over-year, from $2.1M to $2.0M in fiscal year 2026.

Is Nutriband Inc. Warrant profitable?

No, Nutriband Inc. Warrant (NTRBW) reported a net loss of $8.2M in fiscal year 2026.

Nutriband Inc. Warrant (NTRBW) reported diluted earnings per share of -$2.58 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nutriband Inc. Warrant (NTRBW) had EBITDA of -$8.1M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

Nutriband Inc. Warrant (NTRBW) had a gross margin of 27.8% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

Nutriband Inc. Warrant (NTRBW) has a return on equity of -123.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

Nutriband Inc. Warrant (NTRBW) recorded an outflow of $5.1M in free cash flow during fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Nutriband Inc. Warrant (NTRBW) recorded an outflow of $5.1M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

Nutriband Inc. Warrant (NTRBW) had $7.5M in total assets as of fiscal year 2026, including both current and long-term assets.

Nutriband Inc. Warrant (NTRBW) invested $5K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

Nutriband Inc. Warrant (NTRBW) invested $1.9M in research and development during fiscal year 2026.

Nutriband Inc. Warrant (NTRBW) had 12M shares outstanding as of fiscal year 2026.

Nutriband Inc. Warrant (NTRBW) had a current ratio of 6.36 as of fiscal year 2026, which is generally considered healthy.

Nutriband Inc. Warrant (NTRBW) had a liabilities-to-equity ratio of 0.13 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.

Nutriband Inc. Warrant (NTRBW) had a return on assets of -109.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2026, Nutriband Inc. Warrant (NTRBW) held $4.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.1M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Nutriband Inc. Warrant (NTRBW) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Nutriband Inc. Warrant (NTRBW) reported a net loss of $8.2M while operations used $5.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Nutriband Inc. Warrant (NTRBW) reported an operating loss of $8.3M against $23K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Nutriband Inc. Warrant (NTRBW) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top